RAF1 and melanoma: For example, combining rapamycin with sorafenib (a multikinase inhibitor that inhibits Raf-1 and B-RAF) synergistically reduces melanoma cell proliferation, and targeting these two types of signaling pathways simultaneously, may be more effective for treating melanoma than using either agent alone [38].